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Nanotechnology may replace existing treatments for cancer 
 
Ethan Helm* 
Department of Biology 
Lake Forest College 
Lake Forest, Illinois 60045 
 
In 2002, 23% of all deaths in the United States were 
caused by cancer making it the second biggest killer, 
only ranking behind heart disease (Jemal et al., 2005). 
Every year, over a half million Americans die of cancer 
and more than a million are diagnosed with the disease.  
It is also the second biggest killer among children, with 
nearly 12% of all childhood deaths coming from the 
disease (Jemal et al., 2005). 
Cancer is a disease in which cells proliferate 
uncontrollably (Campbell et al., 2002).  Unlike most 
cells, cancerous cells do not display density dependent 
growth, meaning they divide with little spatial regulation 
(Moossa et al., 1990). Moreover, these cells have the 
ability to spread by breaking into blood vessels and 
moving to other systems (Moossa et al., 1990).   
Cancer can be fatal due to a combination of 
its properties.  For instance, cancerous cells lose their 
ability to function normally.  That is, they stop 
responding normally to cellular signals and therefore no 
longer perform their job (McKinnel et al., 1998).  Not 
only do cancer cells cease working, they also affect 
neighboring cells because cell division and metabolism 
require nutrients and energy; eventually the cells 
require more nutrients than the body can provide and 
slowly organ systems begin to fail, a process known as 
cachexia (American Cancer Society, 2000).  
Additionally, the growths themselves can cause 
immense pain or death in hollow organs (such as the 
colon) by blocking the lumen and preventing proper 
function.  Moreover, tumors can cause pressure on the 
brain which can lead to brain failure, seizures, or partial 
lack of function depending on the location of the tumor 
(McKinnel et al., 1998).   
The formation of cancer requires several 
genes to be altered through mutations, which can be 
caused by spontaneous errors in replication or by 
exposure to carcinogens that alter nucleotides or break 
the DNA strand. In order for a mutation to lead to 
cancer, it has to perpetuate the cell cycle (Kruh et al., 
2000).     
The cell cycle is a highly regulated process 
that ultimately results in the division of one cell into two 
(Campbell et al., 2002).  In somatic cells, this cycle 
includes four phases: G1, S, G2, and mitosis (M).  
During G1 phase, the cell grows as it prepares for DNA 
synthesis, S phase.  Then in G2 phase, the cell grows 
in preparation for mitosis, in which the replicated DNA 
is equally divided into two newly formed daughter cells 
(Campbell et al., 2002). 
Errors in the cell cycle are normally corrected 
during specific checkpoints at G1 to S, intra-S phase, 
and S to M.  At these points, the cell cycle is 
temporarily arrested while regulatory enzymes ensure 
that there are no errors in the DNA sequence.  If an 
error is found, the DNA damage is either repaired or the 
cell is tagged by a marker protein to commit suicide 
through apoptosis (Alberts et al., 2003).  If inhibited, the 
cell cannot properly identify damage, and the cell cycle 
continues without the appropriate regulation (Kruh et 
al., 2000). 
 
*This paper was as part of an independent study on Oncology. 
The cell cycle can be perpetuated through 
two types of genetic mutations: oncogenes and tumor 
suppressor genes (Kruh et al., 2000).  Tumor 
suppressor genes normally are involved with the repair 
of damaged DNA.  Thus, whenever these genes are 
inactivated, damaged DNA is not properly repaired 
(Moossa et al., 1990).  According to Ames and Gold 
(1991), every cell in the body experiences 105 DNA 
damaging events daily.  Thus, the regulatory process of 
repairing DNA is an active and important process.  
Tumor suppressor genes can be broken down into two 
categories:  caretakers and gatekeepers (Kruh et al., 
2000).  Gatekeepers have a direct roll in controlling 
cellular proliferation, while caretakers help preserve the 
integrity of the genome by preventing mutations from 
occurring.  An inactivated caretaker does not lead 
directly to tumor initiation, but instead it causes genetic 
instability, which causes subsequent mutations.  In 
contrast, inactivated gatekeepers play a more direct 
role in the tumorigenesis process (Kruh et al., 2000). 
While tumor suppressor genes are 
dangerous when inactivated, oncogenes are only 
hazardous when active, at which point they are capable 
of inducing cancer in normal cells (McKinnel et al., 
1998).  Due to this, oncogenes are highly regulated in 
the body.  Additionally, oncogenes have a wide variety 
of functions.  For instance, some encode for growth 
factors that increase the proliferation of cells, others 
bind to DNA and regulate transcription, and yet others 
code for receptors or ligands involved in the cell cycle 
(Kruh et al., 2000).  If over expressed, however, all of 
them can contribute to the development of cancer by 
promoting cell division (McKinnel et al., 1998).    
Tumorigenesis, or tumor formation, is a 
multistep process requiring more than one active 
oncogene or inactive tumor suppressor gene.  If a 
group of cells has a small number of these mutations, a 
benign tumor may form.  These tumors lack the ability 
to metastasize or spread to other parts of the body.  
However, if the benign tumor has more mutations, it is 
possible for it to become malignant (McKinnel et al., 
1998). 
The process of carcinogenesis involves four 
steps.  The first step is initiation, in which a carcinogen 
reacts with DNA causing a strand break or altering a 
nucleotide to form an adduct (McKinnel et al., 1998).  
Normally, a DNA polymerase repairs this problem, 
however, if the DNA replicates before the repair, the 
error can be permanently fixed into the genome (Kruh 
et al., 2000).  Most errors of this type have no real 
effect on the body, but if a tumor suppressor is 
inactivated or an oncogene activated, the cell has a 
significant growth advantage, and the next step, 
promotion, may begin.  During promotion, a molecule 
called a promoter causes selective proliferation, which 
may lead to the formation of multiple benign tumors 
(Alberts et al., 2003).  Through one or more additional 
genetic alterations, the third step, known as 
progression, may occur.  In this step, the tumor cells 
develop a significant growth advantage, which is so 
strong that they are able to break through the blood 
vessel membrane and travel to other areas through the 
process of metastasis.  This actual conversion is the 
last step, and is referred to as malignant conversion 
(McKinnel et al., 1998).     
This further establishes the importance of 
multiple mutated tumor suppressor genes and 
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oncogenes in cancer development.  In other words, the 
growth advantage brought about by one mutation is not 
significant enough to overcome the natural immunity of 
the body.  Tumors of this nature are contained because 
they are unable to break into the blood vessels 
(McKinnel et al., 1998).  However, through multiple 
mutations, the growth advantage may be increased 
sufficiently to break through blood vessel membranes 
(McKinnel et al., 1998).  For many years, scientists had 
no clue how to deal with this growth advantage.  As a 
result, cancer was virtually untreatable, and even today, 
many types have no specific treatment. 
Chemotherapy’s potential to treat cancer was 
discovered during December of 1943, when an Allied 
warship holding mustard gas exploded (Williams, 
2000). As a response to this, the army performed 
autopsies on the soldiers, which showed that their bone 
marrow had been destroyed by the gas, thereby 
inhibiting the production of red blood cells, white blood 
cells, and platelets. Accordingly, scientists 
hypothesized that the chemical may be used to fight 
cancer. To test this hypothesis, a chemical derived from 
mustard gas, known as mustine, was given to 
Hodgkin’s disease patients and, even in some patients 
with late-stage Hodgkin’s, the disease responded to the 
drug (Williams, 2000). In fact, this drug is still a key 
component of the MOPP (mustine, vincristine, 
procarbazine, and predinisone) regimen (Rüffer et al., 
1998), which is one of the two primary treatments for 
Hodgkin’s disease, the other being ABVD (Adriamycin, 
bleomycin, vinblastine, and dacarbazine) (Kennedy et 
al., 2003; Murphy et al., 1997). 
Unfortunately, the treatments commonly used 
for cancer (radiation and chemotherapy) are both 
deleterious to the health of patients, and can actually 
cause death themselves by weakening the immune 
system and making patients more susceptible to other 
diseases (Schnell et al., 2003).  The problem with these 
treatments is that they are not selective. That is, they 
act on all rapidly dividing cells causing the most 
recognizable symptom of cancer treatment:  loss of 
hair.  These treatments also inhibit the production of 
erythrocytes and white blood cells, causing patients to 
become anemic and neutropenic (Schnell, 2003).  
Anemia, a state of insufficient O2 delivery to tissues, 
can cause problems with blood clotting, as well as lead 
to dizziness and lethargy.  Neutropenia refers to a 
decrease in the number of neutrophils in the blood 
signifying a weakened immune system.  When 
neutropenic, patients are more susceptible to 
secondary infections; even a common cold can be fatal.  
Furthermore, chemotherapy triggers neuroreceptors, 
such as those that bind dopamine and serotonin, which 
stimulate nausea and cause vomiting (Schnell, 2003).    
Not only are chemotherapy and radiation 
dangerous, they also are not completely effective.  
According to Dr. Frank Balis, “We attribute our inability 
to cure many adults with more common forms of solid 
tumors to the ineffectiveness of chemotherapy to these 
diseases” (1998).  In fact, the average five year survival 
rate among all cancers in the United States is only 63% 
(Jemal et al., 2005). Thus, newer and more effective 
treatments are being sought by scientists and 
pharmaceutical companies alike. 
In the last few years, the field of 
nanotechnology has exploded as some scientists 
believe tiny objects known as nanoparticles may be 
able to help treat a variety of diseases, including 
cancer.  By definition, nanoparticles can range in size 
from 1 to 100 nanometers (Cervellino et al., 2005).  The 
nanoparticles being studied have a variety of 
compositions, shapes, and sizes.  The most common 
composition includes either a carbon backbone or the 
presence of an inorganic metal, such as a gold (Zharov 
et al., 2003).   
Recently, scientists have discovered that 
nanoparticles can easily enter cells.  However, it is 
uncertain how this occurs. Dai et al. (2005) claims the 
influx of nanoparticles occurs by endocytosis.  In 
contrast, Bianco et al. (2005) suggest the process 
happens through insertion and diffusion of particles 
through the lipid bilayer of the cell membrane.   
Furthermore and surprisingly, these particles can be 
linked to proteins, such as antibodies, and still enter 
cells (Dai et al., 2005).  Fortunately, cancer cells 
express certain receptors that are not expressed by 
normal cells.  Thus, nanoparticles attached to 
antibodies for these receptors can be directed to 
cancerous cells exclusively (Dai et al., 2005). 
The ability of nanoparticles to selectively 
enter cancer cells has duel significance.  Firstly, 
nanoparticles can work as drug deliverers.  For 
instance, by linking certain proteins, such as tumor 
necrosis factor (TNF), a protein with known antitumor 
activity, to the particles a new mechanism for fighting 
cancer can be utilized (Paciotti et al., 2004).  Secondly, 
nanoparticles have been shown to absorb different 
wavelengths of light than the body, and when exposed 
to appropriate wavelengths nanoparticles heat up, but 
the body does not.  This method, known as 
hyperthermia, can be used to selectively kill cancer 
cells by heating nanoparticles that are linked to 
antibodies (Ito et al., 2003a).   
The specificity of these techniques is key, 
because unlike the deleterious effects of chemotherapy 
and radiation, treatment with nanoparticles should 
result in no major side effects.  Furthermore, in 
preliminary studies, hyperthermia and drug delivery 
have both been successful, and currently, both 
hyperthermia and drug delivery are being heavily 
investigated as treatments for cancer (Dai et al., 2005; 
Onishi et al., 2003).  The purpose of this review is to 
discuss the nanoparticle techniques of hyperthermia 
and drug delivery and determine whether they may one 
day replace the current techniques of chemotherapy 
and radiation as a treatment for cancer. 
 
Imaging to Detect Cancer Cells 
 
Beyond having the power to treat cancer, nanoparticles 
may also be used to detect the disease.  Moreover, 
some therapies hope to utilize hyperthermia in such a 
way that diagnosis and treatment can occur together. 
There are several techniques scientists are 
investigating to improve cancer detection and couple it 
with hyperthermia (Loo et al., 2004).  
 One popular technique involves attaching 
bioconjugates, such as antibodies, to the nanoparticles.  
Loo et al. (2005) attempted to analyze this technique by 
utilizing the tendency of breast carcinoma cells to 
overexpress the HER2 biomarker.  Thus, by 
conjugating an antibody of HER2 to a PEG linker 
complex, which enhances biocompatibility and blood 
flow, and then attaching the complex to a gold 
nanoshell, the particle is linked exclusively to breast 
cancer cells (Loo et al., 2005).  
Using this, Loo et al. (2005) cultured three 
types of cells:  cells with the anti-HER2/PEG/nanoshell 
complex, cells with a non-cancer specific antibody, and 
cells without nanoshells.  These cells were viewed with 
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a darkfield microscope sensitive to scattered light, and 
only the Anti-HER2 cells showed much light scattering 
(Figure 1).  In contrast, the cells with the non-specific 
antibody showed some light scattering, but it was not as 
dense.  This illustrates that the Anti-HER2 treated cells 
attached exclusively to cancer cells, and exposure of 
light identified cancer cells.  Furthermore, when treated 
with near-infrared (NIR) light of around 800 nm, 
cytotoxicity was observed only in the presence of the 
cells treated with Anti-HER2 nanoshells (Figure 1) (Loo 
et al., 2005).  Thus, the hyperthermia treatment was 
successful, but only with the Anti-HER2 treated cells.   
 
Hyperthermia to Kill Cancer Cells 
 
As mentioned earlier, hyperthermia is the killing of cells 
through the heating of nanoparticles.  One of the 
problems of hyperthermia is containing the heat in such 
a way that it does not affect other cells.  To combat this, 
scientists use specific types of nanoparticles for 
hyperthermia, such as magnetite cationic liposomes 
(MCLs) (Kobayashi et al., 2005).  These spherical 
particles contain a positively charged phospholipid 
exterior that interacts with the negatively charged cell 
surface, easily entering cells.  The inside of the MCLs is 
a 10 nm magnetite nanoparticle (Kobayashi et al., 
2005).  Additionally, these particles have maintained 
the ability to bind to antibodies and can provide tumor-
specific contrast enhancement. 
 
Gene Therapy/Hyperthermia Combination 
Hyperthermia appears to be effective in some cases by 
itself, however, in advanced stages of several types of 
cancer, such as melanoma, it may not be sufficient (Ito 
et al., 2003a).  Furthermore, to treat cancer, 
hyperthermia requires many treatments.  However, in 
conjunction with other processes, scientists hope to find 
a way to use one round of hyperthermia to eradicate 
the disease.  The combination therapies revolved 
around the use of substances to boost anti-tumor 
immunity.  Thus, in addition to hyperthermia, the cancer 
cells will be assaulted by a revamped immune system 
(Ito et al., 2003b).  Ito et al. (2003a) have been 
analyzing the use of one such protein, heat shock 
protein 70 (HSP70), in conjunction with hyperthermia 
with MCLs.  Expression of this protein protects cells 
from heat-induced apoptosis (Mosser et al., 2000), but 
recently, it has also been shown to be a key component 
in immune reactions (Srivastava et al., 1998).   
 To analyze HSP70 gene therapy combined 
with hyperthermia, Ito et al (2003a) analyzed how mice 
with malignant melanoma reacted to tumors that had 
been given a plasmid containing human-inducible 
hsp70 complimentary DNA.  The primary finding was 
that hsp70 gene transfer successfully boosted the 
immune system during hyperthermia (Ito et al., 2003a).  
They determined this by comparing tumor size after 
exposure to hsp70 containing plasmid, hyperthermia, 
and the combined treatment.  Both treatments alone 
showed improvement, but in each case, additional 
treatments would be required because the tumors 
began to grow again at around the tenth day.  The 
combined therapy, however, completely eradicated 
cancer in 3 of the 10 mice with only one treatment.  
Because hyperthermia can be used multiple times 
without any negative effects, it is believed that the 
cancer could have been eradicated in the other mice 
with subsequent treatments.  Moreover, tumors with the 
combined therapy were 16 times smaller than the 
hyperthermia only treated tumors after thirty days, and 
24 times smaller than the tumors given hsp70 (Ito et al., 
2003a).   
 
Hyperthermia with Dendritic Cell Addition 
The use of immune triggering proteins is not the only 
way to boost anti-tumor activity.  For instance, mature 
dendritic cells (DC) are an integral part of a normal 
immune response, which stimulate the growth of CD4+ 
T cells, CD8+ cytotoxic T lympocytes, and natural killer 
cells (Palucka et al., 1999).  Unfortunately, mature DCs 
cannot take up antigen, and thus addition of these cells 
would not result in the proper immune response.  
Injection of immature DCs, however, has been reported 
to cause antitumor activity (Celluzzi et al., 1998).  
Tanaka et al. (2005) decided to go straight to 
the source by actually adding additional dendritic cells 
(DC) after mouse EL4 T- lymphoma tumors were 
treated with hyperthermia.  While only 1 in 8 of the mice 
Figure 1. Imaging and hyperthermia using nanoparticles. Imaging and therapy of SKbr3 breast cancer cells using HER2 linked 
nanoshells.  Top row:  darkfield imaging of of HER2 expression based on light scattering.  Bottom row:  cell viability assessed through 
calcein staining with exposure to ~820 nm near infrared (NIR).  Cell death was observed only in cells treated with anti-HER2 nanoshell
take from (Loo et al., 2005).   
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treated with hyperthermia alone had complete tumor 
regression, 6 in 8 of the mice treated with hyperthermia 
and immature DCs had complete tumor regression.  
Based on this, it appears the tumor cells killed by 
hyperthermia release antigen proteins which the 
immature DCs take up and are then presented to T 
cells via MHC class I and/or II antigens (Tanaka et al., 
2005). 
 
Drug Delivery Using Nanoparticles 
 
Drug delivery is the carrying of drugs using 
nanoparticles specifically to the cells causing the 
disorder.  In the case of cancer, these drugs are 
frequently known chemotherapeutic agents.  
Intravenously, these drugs cause a variety of side 
effects. However, by linking them to nanoparticles the 
drugs go directly to the source and do not affect healthy 
cells (Paciotti et al., 2004).  As is the case with 
hyperthermia, certain types of nanoparticles are better 
adapted for drug delivery than others.  For instance, 
nanoparticles composed of colloidal gold easily attach 
various drugs.  Colloidal gold is a dispersed solution of 
nanoparticles of Au0 (Paciotti et al., 2004).  Additionally, 
polybutyl cyanoacrylate (PCB) nanoparticles attach 
drugs, protect them against enzymatic degradation, 
reduce their toxic effects, and limit distribution of the 
drug outside the target area (Reddy et al., 2004a).   
 
Tumor Necrosis Factor and Colloidal Gold  
Tumor necrosis factor (TNF) is a cytokine that affects 
coagulation, lipid metabolism, insulin resistance, and 
proper function of endothelial cells (Paciotti et al., 
2004).   It is produced during immune response 
primarily by monocytes and macrophages and has the 
ability to induce death in tumor cells (Elliott et al., 1994).  
Unfortunately, TNF causes systemic toxicities that have 
prevented it from being used as an anti-cancer drug 
(Furman et al., 1993).  This toxicity can be attributed to 
rapid uptake of TNF by the reticuloendothelial system 
(RES) (Paciotti et al., 2004).  Through the use of 
colloidal gold nanoparticles, Paciotti et al. (2004) were 
able to construct a vector which can avoid detection 
and clearance by the RES.  Thus, the nanoparticles 
(PT-cAu) delivered TNF specifically to tumor cells, 
eliminating the associated systemic toxicity.   
Next, Paciotti et al. (2004) compared 
treatment using native TNF and PT-cAu-TNF which 
showed both reduced tumor size in a concentration 
dependent manner.  However, mice given 12 µg native 
TNF suffered 25% fatality and all given 24 µg native 
TNF died whereas none of the mice treated with PT-
cAu-TNF perished.  Furthermore, Figure 2b illustrates 
that while 15µg of Native TNF has approximately the 
same affect on tumor size as PT-cAu-TNF through 16 
days, the survival rate using the native form is 40% 
lower.  Thus, without the colloidal gold nanoparticles, 
TNF is extremely toxic.  These nanoparticles help TNF 
circumvent the RES and enter selectively into cancer 
cells, which ultimately causes tumor cells to die 
(Paciotti et al., 2004).  
 
Localized Chemotherapy 
As mentioned earlier, the main problem with 
chemotherapy is that it is not tumor specific.  Thus, 
chemotherapy drugs tend to act on all rapidly dividing 
cells.  Through the use of nanoparticles, however, the 
same drugs can be linked specifically to cancer cells at 
higher concentrations for longer periods of time.  Thus,   
the drugs not only have increased cytotoxic activity, but 
also adverse side effects are limited (Alberts et al., 
1985).  
 
Doxorubicin 
Doxorubicin hydrochloride (Dox), also known as 
adriamycin, is a cytotoxic anthracycline that is an 
essential component of chemotherapeutic regimens 
used to treat acute lymphoblastic leukemia, breast 
carcinoma, Hodgkin’s and Non-Hodgkin’s lymphoma 
(Murphy et al., 1997).  The drug works by halting DNA 
replication, and thereby preventing further proliferation 
of the disease (Reddy et al., 2004a).  
Fortunately, Dox’s anti-tumor activity has 
been widely documented, and there is no reason to 
think it would behave differently if attached to a 
nanoparticle.  At the same time, intravenous treatment 
of Dox causes systemic toxicity that can cause severe 
diarrhea, neutropenia, anemia, hair loss, and heart 
damage.   Thus, scientists are investigating the use of 
different types of nanoparticles that can be used to 
deliver Dox directly to cancer cells, ultimately 
preventing systemic toxicity (Wilkes et al., 2000).   
Reddy and Murthy (2004a) investigated this 
by analyzing two different polymerization techniques for 
making polybutyl cyanoacrylate (PRC) nanoparticles: 
dispersion polymerization (DP) and emulsion 
polymerization (EP).  The result of each polymerization 
technique produced structurally similar molecules.  The 
difference, however, was that the EP nanoparticles 
were smaller.  Therefore, Reddy and Murthy (2004a) 
sought to find out whether the size difference of the 
PRCs affected the nanoparticles’ ability to deliver Dox.  
They found that EP particles provided a longer half-life 
of Dox in the blood and a lower tissue distribution, 
which is consistent with their previous finding that EP 
nanoparticles have enhanced permeability and 
retention effects (Murthy and Harivardhan, 2003).  
Conversely, DP nanoparticles were quickly cleared into 
the RES.  Both techniques demonstrated a significant 
increase in bioavailability of Dox compared to 
intravenous injection of Dox solution (Reddy and 
Murthy., 2004a).  Together, the experiment identified 
the EP nanoparticles as a potential method of 
improving Dox therapy by reducing systemic toxicity 
(Reddy and Murthy, 2004a). 
 Following the polymerization study, Reddy et 
al. (2004b) examined the affect of Doxorubican loaded 
poly(butyl cyanoacrylate) (DPBC) nanoparticles on 
Dalton’s lymphoma.  They found that the DPBC 
nanoparticles sequestered in the tumor after 
subcutaneous injection much better than did free Dox.  
Additionally, they noted that there was a low amount of 
Dox found in the heart from the DPBC nanoparticles, 
and confirmed that Dox delivered by DPBC 
nanoparticles has an increased retention time within 
tumors.  This confirms the results of the previous 
experiment, and also shows that cardiac toxicity may be 
limited through this technique. 
 Ma et al. (2004) developed another type of 
nanoparticle to be used for Dox delivery to tumor cells.  
The particles, known as carbon magnetic nanoparticles 
(CMNP), were created using a new technology known 
as dense medium plasma (DMP) technology.  The 
particles consist of a carbon-based host structure with 
iron and iron oxide particles evenly dispersed (Ma et al., 
2004).  The CMNP-Dox and intravenous free Dox were 
applied to osteosarcoma cells to test antiproliferative 
activity.  The results showed that at the highest dose,
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 free Dox had no significant effect on the tumor cells 
compared to CMNP-Dox, which completely stopped 
proliferation at 120 µg/ml Dox.  Interestingly, at 240 
µg/ml, CMNP-Dox had a reduced effect, believed to be 
because of steric hindrance caused by excess 
nanoparticles (Ma et al., 2004).  One of the chief 
advantages of this system, however, is that it can be 
made in one step under atmospheric pressure using 
inexpensive chemicals, such as benzene and 
acetonitrile, making it both effective and cost efficient 
(Ma et al., 2004). 
 
Paclitaxel  
Paclitaxel is a chemotherapy drug that can be used to 
treat Kaposi’s sarcoma and metastatic breast, ovarian, 
and bladder cancer (Wilkes et al., 2000).  It is an anti-
microtubule compound that prevents continuation of the 
cell cycle and thus proliferation (Wientjes et al., 2004).  
In the case of bladder cancer, doxorubicin and 
mitomycin C are ineffective treatment options due to 
their inability to pass through the transitional epithelium 
in the wall of the bladder known as the urothelium.  
Since paclitaxel is lipophilic, however, it can freely pass 
through the urothelium (Wientjes et al., 2004).  The 
FDA approved formulation for paclitaxel includes the 
solvent Cremophor.  Cremaphor causes paclitaxel to 
become entrapped in the micelles of the bladder, which 
lowers the drugs ability to penetrate the urothelium 
(Knemeyer et al., 1999).  To combat this, Wientjes 
(2003) used DMSO as a surface-active agent that 
disrupted Cremaphore micelles and enabled paclitaxel 
to be delivered to the tumors; however, this technique 
caused increased urine production and associated drug 
removal.  Consequently, with less time in contact with 
the cancerous cells, paclitaxel was less effective.   
Wientjes’s et al. (2004) second attempt to 
facilitate the transfer of paclitaxel through the 
urothelium utilized gelatin nanoparticles loaded with the 
drug.  These nanoparticles are hydrophilic and thus 
uptake fluid rapidly allowing for paclitaxel to be released 
easily.  This is important because the quicker the drug 
is released, the longer its exposure to cancer cells 
before urination.  The concentration of paclitaxel in the 
urine, which was collected during treatment, was 2.6x 
that of the cremophor/EtOH formula.  Additionally, 87% 
of the drug was released in two hours (Wientjes, et al., 
2004), compared to only 45% after 3 days for 
paclitaxel-loaded poly(ethylene oxide)- poly 
(lactide/glycolide) nanospheres used to regulate 
smooth muscle cell regulation (Suh et al., 1998).  In 
summary, paclitaxel loaded gelatin nanoparticles were 
able to penetrate the urothelium of the bladder and 
rapidly release the drug, making them a promising 
treatment for bladder cancer (Wientjes et al., 2004).      
 
Gene Delivery using Nanoparticles 
 
Nanoparticles can deliver proteins with anti-tumor 
activity into tumor cells and additionally, they can be 
used to deliver chemotherapeutic drugs directly to 
tumors, avoiding systematic toxicity.  The versatility of 
these small particles also allows them to transport 
plasmid DNA with tumor suppressor genes to tumor 
cells.  This causes a tumor suppressing protein to be 
produced which induces tumor cell apoptosis, 
effectively fighting the cancer (Ramesh et al., 2004). 
 
MDA-7 
 First identified in human melanoma cells 
(Jiang et al., 1995), the human melanoma 
differentiation associated gene 7 (mda-7 or IL-24) is a 
tumor suppressor gene.  In late stage human 
melanoma, MDA-7 protein is absent, whereas in early 
stage melanoma it is present.  Accordingly, this gene 
Figure 2:  TNF effect on tumor volume in mice MC-38 colon carcinoma tumors. 
a.)  Antitumor efficacy of native TNF and the cAu-TNF vector.  Mice with MC-38 colon carcinoma tumors were intravenously injected with 
increasing concentrations of native TNF of cAu-TNF vector (n=4/group/dose).  Tumors were measured 10 days after treatment using three 
dimensional measurements  (L x W x H).  b.) Antitumor efficacy of native TNF and PT-cAu-TNF vector using one group as a control.  Two
groups with either 7.5 or 15 g of intravenously injected PT-cAu-TNF.  Another two groups were intravenously injected with 7.5 or 15 µg of 
native TNF.  The size of tumors were then measured on various days (Paciotti et al., 2004). 
 
 60 
product is likely involved with progression of the 
disease (Ellerhorst et al., 2002).  Furthermore, the 
protein is absent in a variety of human tumors including 
lung, breast, and colorectal carcinomas and sarcomas, 
and thus, it is believed to be involved in both the 
development and progression of these human cancers 
(Chada, et al., 2003). 
 Previous studies have shown that through 
using adenoviral vectors, expression of MDA-7/IL-24 
triggers cytotoxic related cell death and growth 
suppression in several human cancer cells (Ramesh et 
al., 2004).  Moreover, normal cells are not affected by 
exposure to mda-7gene, making it a potentially strong 
anti-tumor therapy.  In 2003, Chada et al. used an 
adenoviral receptor to deliver mda-7 to tumors in the 
lungs.  The results were promising, because this 
procedure caused expression of MDA-7 induced 
apoptosis in the tumors.  Unfortunately, the adenovirus 
vector can cause an immune response and liver toxicity 
(Vlachaki et al., 2002).  Therefore, a new vector for 
mda-7 delivery to disseminated cancers is needed. 
 Ito et al. (2003c) demonstrated that DOTAP: 
cholesterol nanoparticles can transport tumor 
suppressor genes to tumors in the lungs and increase 
the transgrene expression of these genes.  Based on 
this, Ramesh et al. (2004) tested the use of cationic 
DOTAP: cholesterol (Chol) nanoparticles as a vector for 
delivery of mda-7 gene.  They found that cells treated 
with the DOTAP/mda-7 gene showed significantly fewer 
tumors (Figure 3).  Additionally, they found no 
resistance to multiple treatments with this therapy, as 
well as no systematic toxicity.  Furthermore, the 
treatment was still successful in immunodeficient and 
immunocompetent organisms.  Thus, using DOTAP: 
Chol nanoparticles as a vector for the mda-7 gene is a 
novel approach for cancer therapy that shows much 
promise (Ramesh et al., 2004).  
 
Discussion 
 
In this paper, I have chronicled three promising 
techniques for treatment of cancer using nanoparticles: 
hyperthermia, drug delivery, and gene therapy.  These 
techniques each have several advantages over the 
current treatments of radiation and chemotherapy.  
Firstly, neither of these treatments causes systematic 
toxicity.  In fact, both hyperthermia and drug delivery 
can be directed specifically to cancer cells.  Ultimately, 
this is advantageous because it greatly reduces the 
physically and psychologically demanding side effects 
of chemotherapy and radiation, which include, but are 
not limited to anemia, neutropenia, hair loss, diarrhea, 
sterility, and nausea.   
These side effects are thought to be 
worthwhile because of chemotherapy’s effect on 
cancer, but all cancer cells are not responsive to 
chemotherapy.  Furthermore, some cancers develop 
resistance to chemotherapeutic drugs (Gottesman, 
2002).  There are several reasons for this.  As 
mentioned in the beginning, tumor cells have a variety 
of mutations, and all tumor cells do not have the same 
mutation.  Some mutations allow cells to randomly 
develop resistance to drugs because they no longer 
express the protein receptors to which the drug 
interacts.  Thus, the cells without the receptor have a 
growth advantage, and if another drug is not used, 
these cells will proliferate rapidly (Gottesman, 2002).  
Additionally, tumor cells may produce more target 
proteins than the drugs can bind.  Since 
chemotherapeutic agents are not specific, the 
concentration of the drugs cannot be raised, as other 
systems of the body would be effected as well 
(Gottesman, 2004).  Furthermore, enhanced 
amplification of the MDR1 (Multiple Drug Resistance) 
gene results in the encoding of a large transmembrane 
protein which can stop certain drugs from entering a 
cell and also eject drugs already in it (Bredel et al., 
2002).        
With chemotherapy, any form of resistance 
requires another type of drug; however, nanoparticles 
may hold the key to circumventing such resistance.  
Early trials with hyperthermia and gene delivery show 
that each technique may be used multiple times.   
Hyperthemia, for instance, does not work on hindering 
processes inside the cell, but instead, it heats the cell 
up to such high temperatures that it denatures proteins 
and DNA (Dai et al., 2005).  Heat shock proteins that 
stabilize proteins to prevent denaturing are themselves 
denatured when exposed to heat of this magnitude (Ito 
et al., 2003).  Thus, hyperthermia can be done 
Figure 3- Mice treated with mda-7 exhibit a lower number of tumors. 
Mice with A549 and UV2237m lung tumors were treated daily for a total of six doses (50 g/dose) with phosphate-buffered saline 
(PBS), DOTAP:Chol-chloramphenicol acetyl transferace (CAT) nanoparticles, or DOTAP: Chol-mda-7 nanoparticles.  Tumor growth 
was only inhibited by DOTAP:Chol-mda-7 nanoparticles (P<0.05; Ramesh et al., 2004).   
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repeatedly without detrimental effects to other systems 
or the threat of tumor cells becoming resistant to it (Dai 
et al., 2005).  Moreover, through gene delivery, 
expression of tumor suppressor genes inside tumors 
can be controlled, so in essence, tumors are forced to 
fight themselves.  Early experiments suggest, that using 
the mda-7 gene in this manner can be performed 
repeatedly and cells develop no resistance (Ramesh et 
al., 2004).   
 While hypothermia and gene therapy appear 
to circumvent resistance, through the use of higher drug 
concentrations and exposure time, localized drug 
delivery provides another option.  The use of 
nanoparticles allows for higher concentrations of drugs, 
such as native tumor necrosis factor and doxorubicin, to 
be used.  This is possible because the nanoparticles 
specifically target cancer cells, and thus, there will be 
no associated systemic toxicity.  Because a higher 
amount of the drugs can be used, the initial treatment 
has a larger effect, as more of the drug is able to 
interact with the tumor cells.  Additionally, a second 
treatment can be administered much more rapidly 
afterward, since the rest of the body does not have to 
recover.  Together, there is a much smaller chance that 
the tumor would develop resistance, because treatment 
can take a shorter period of time.  However, it is 
possible that some of the tumor cells have innate 
resistance, in which case, another drug would have to 
be used.     
 In summary, the techniques of drug delivery 
and hyperthermia using nanoparticles have the 
potential to decrease side effects while increasing the 
cure rate of cancer patients.  These techniques promise 
a substantial improvement over chemotherapy and 
radiation.  Over the next few years, if the research 
conducted on nanoparticles continues to find promising 
results, the treatment of cancer all over the world may 
be substantially altered.  The cure for cancer may in 
fact be close at hand. 
 
Note: Eukaryon is published by students at Lake Forest 
College, who are solely responsible for its content. The 
views expressed in Eukaryon do not necessarily reflect 
those of the College. Articles published within Eukaryon 
should not be cited in bibliographies. Material contained 
herein should be treated as personal communication 
and should be cited as such only with the consent of 
the author.    
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